Robustness and fragility of evidence supporting systemic thrombolysis in acute pulmonary embolism
Journal of Thrombosis and Thrombolysis · 2026
DOI: 10.1007/s11239-026-03344-x ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2026. Verfasst von Marco Zuin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44100, Italy. zuinml@yahoo.it. Hauptthemen laut MEDLINE: Pulmonary Embolism, Thrombolytic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Systemic thrombolysis is recommended for high-risk PE and select intermediate-risk patients. We assessed the robustness of RCT evidence comparing systemic thrombolytic therapy with standard anticoagulation. We systematically reviewed RCTs of intravenously administered alteplase or tenecteplase versus heparin. The primary endpoint was all-cause mortality; secondary endpoints included recurrent PE, clinical deterioration in intermediate-risk patients, and major bleeding. Fragility index (FI) or reverse FI (RFI) and fragility quotient (FQ) or reverse FQ (RFQ) were calculated to assess outcome stability. Absolute and relative risk reductions, number needed to treat (NNT), and number needed to harm (NNH) were also derived. Nine RCTs enrolling 1,682 patients met inclusion criteria. Overall, systemic thrombolysis was associated with a nonsignificant reduction in mortality (1.7% vs. 3.8%; RR 0.73; 95% CI 0.39-1.38; p = 0.33) with moderate robustness (RFI = 8; RFQ = 0.004; NNT 91; RRR 27%; ARR 2.1%). Mortality was highly fragile in high-risk PE (RFI = 0) and fragile in intermediate-risk patients (RFI = 4). Systemic thrombolysis moderately reduced recurrent PE (RR 0.42; 95% CI 0.18-0.97; FI = 5; RFQ = 0.002) and prevented clinical deterioration in intermediate-risk patients (RR 0.31; 95% CI 0.15-0.65; FI = 8; RFQ = 0.006; NNT 29; RRR 71%; ARR 3.5%). Major bleeding was robustly increased (FI = 30; RFQ = 0.001; NNH 17), mainly driven by tenecteplase (FI = 9; RFQ = 0.007; NNH 11), whereas alteplase showed no significant increase (RFI = 3). Mortality benefit of systemic thrombolysis is fragile, while major bleeding risk is robust, underscoring the limitations of current guidelines and the need for adequately powered RCTs to inform individualized treatment in high- and intermediate-risk PE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44100, Italy. zuinml@yahoo.it.
- Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padova, Padua, Italy. zuinml@yahoo.it.
- PhD Program in Translation Specialistic Medicine "G.B. Morgagni", Curriculum Cardiovascular Sciences University of Padua, Padua, Italy. zuinml@yahoo.it.
- Department of Cardiology, Madre Teresa Di Calcutta Hospital, AULSS 6 Ospedali Riuniti Padova Sud, Monselice, Italy. zuinml@yahoo.it.
- Department of Medicine, University of Padua, Padua, Italy.
- Internal, Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy.
Zitieren
APA
Zuin, M., Ageno, W., Vedovati, M. C., Chopard, R., Goldhaber, S. Z., & Simioni, P. (2026). Robustness and fragility of evidence supporting systemic thrombolysis in acute pulmonary embolism. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-026-03344-x
Vancouver
Zuin M, Ageno W, Vedovati MC, Chopard R, Goldhaber SZ, Simioni P. Robustness and fragility of evidence supporting systemic thrombolysis in acute pulmonary embolism. Journal of Thrombosis and Thrombolysis. 2026. doi:10.1007/s11239-026-03344-x
BibTeX
@article{Zuin2026,
author = {Zuin, Marco and Ageno, Walter and Vedovati, Maria Cristina and Chopard, Roman and Goldhaber, Samuel Z and Simioni, Paolo},
title = {Robustness and fragility of evidence supporting systemic thrombolysis in acute pulmonary embolism},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2026},
doi = {10.1007/s11239-026-03344-x}
}
EUVIMED